Modine Manufacturing Company vs Vertex Pharmaceuticals Incorporated — how do they compare? Modine Manufacturing Company trades at $245.92 (market cap $12.18B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10× Modine Manufacturing Company's market cap. Which is the better fit depends on your goals.
| MOD | VRTX | |
|---|---|---|
Market Cap | $12.18B | $121.95B |
Sector | Technology | Health |
52-Week High | $306.89 | $529.59 |
52-Week Low | $93.71 | $366.54 |
Enterprise Value | $12.54B | $116.69B |
Signals from Pluang's Aura AI — not financial advice
MOD trades at $227.88, down 0.64% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.71 exceeding expectations. Revenue reached $2.58B in 2025, though net income margin is modest at 3.82%. Recent news includes institutional buying and executive appointments, while technical support sits near $221.
Analyst consensus is bullish with a $328.80 price target, but high P/E of 101.48 suggests premium valuation. Risks include margin pressure from supply chain challenges and competitive threats in data center cooling. The stock offers growth potential if margin expansion continues, but investors face volatility from technical weakness and execution risks.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →